VHIO´s Director of Clinical Research and PI of the Gastrointestinal Tumours Group, Josep Tabernero talks to ecancer Managing Editor Gordon McVie about the breaking research he presented at the 2011 European Multidisciplinary Cancer Conference, Stockholm, 23 – 27 September including results from VELOUR, a Phase III Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients with Previously Treated Metastatic Colorectal Cancer (MCRC). FOL – folinic acid (leucovorin), F – fluorouracil (5-FU) and IRI – irinotecan.
